A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 601–700 of 1,003
Zhou, X., Song, S. J., Guo, C. Y., Chen, Q., Wong, G. L., Ye, T.-R., Goh, G. B., Bee, Y. M., Lian, L., Yip, T. C., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101645 · Cited by 19
“36 36–38 Given the increased risk of LRE in the liver-specific MASLD subtype, early and targeted screening is crucial to detect liver fibrosis progression and HCC. Non-invasive tools, such as VCTE, should be used regularly to assess liver stiffness, with a liver biopsy considered when further…”
Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities
Geng, Y., Liu, L., Sun, Y., Guo, L., Wu, Y., & Jia, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1705723 · Cited by 17
Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease
Saliba‐Gustafsson, P., Härdfeldt, J., Pedrelli, M., & Parini, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210881 · Cited by 10
“Low-density lipoprotein cholesterol (LDL-C) levels decreased significantly from baseline to week 24: 13.6% in the 80 mg group and 16.3% in the 100 mg group, in stark contrast to the negligible 0.1% reduction observed in the placebo group [97].”
InfluentialImmunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD
Migni, A., Bartolini, D., Ceccarini, M. R., Galli, C., Cavaliere, G., Garetto, S., Lucci, J., & Galli, F. (2026) · Progress in Lipid Research · doi:10.1016/j.plipres.2026.101380 · Cited by 10
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Self-citationRelevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 9
Tachi, K., Agyei-Nkansah, A. A., Atiase, Y., Forkuo, B., & Agyen-Frimpong, V. A. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002294 · Cited by 10
Pavlides, M., Vali, Y., Mózes, F. E., Wonders, K., Akhtar, S., Hockings, P. D., Shumbayawonda, E., Pepin, K., Fernández-Lizaranzu, I., Leeming, D. J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04496-2 · Cited by 12
Self-citationResmetirom: Finally, the Light at the End of the NASH Tunnel?
Lonardo, A. (2024) · Livers · doi:10.3390/livers4010010 · Cited by 8
“However, recently, Harrison et al. [4], based on an analysis conducted in approximately one thousand individuals, published a breakthrough article announcing that, irrespective of the oral dose used (i.e., 80 mg or 100 mg daily), resmetirom was better than placebo regarding the outcomes of resolved…”
BackgroundMatsuda, T., Kaji, K., Nishimura, N., Asada, S., Koizumi, A., Tanaka, M., Yorioka, N., Tsuji, Y., Kitagawa, K., Sato, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38647 · Cited by 8
“A recent Phase III trial has shown promising results for resmetirom, a thyroid hormone receptor beta-selective agonist, in improving liver fibrosis in patients with MASH [7].”
BackgroundTai, T., Shao, Y.-Y., Zheng, Y.-Q., Jiang, L., Han, H.-R., Yin, N., Li, H.-D., Ji, J., Mi, Q., Yang, L., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1496639 · Cited by 9
The Biology and Clinical Implications of PCSK7
Sachan, V., Susan‐Resiga, D., Lam, K., & Seidah, N. G. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae031 · Cited by 9
Ren, T., Eslam, M., & Fan, J. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0558 · Cited by 11
“However, in the phase 3 clinical trial involving biopsy-proven MASH patients, resmetirom only achieved MASH resolution without worsening of fibrosis in fewer than 30% participants and ≥1 stage fibrosis improvement without worsening of the MASH in around 25% participants 15 .”
BackgroundStefan, N., Hartleb, M., Popovic, B., & Varona, R. (2024) · Trials · doi:10.1186/s13063-024-08208-4 · Cited by 6
“Furthermore, res-metirom treatment in patients with MASLD did not improve estimates of insulin resistance [47], which may be important to decrease the elevated cardiometabolic risk that is often observed in patients with MASLD [48].”
BackgroundLei, H. C., Khan, M. S. H., Zu, Y., Liu, J., & Wang, S. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158482 · Cited by 9
Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease
Matteo, M. V., Gualtieri, L., Bove, V., Palumbo, G., Pontecorvi, V., Siena, M. D., Barbaro, F., Spada, C., & Boškoski, I. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2387231 · Cited by 7
“The approval was based on the results from the MAESTRO clinical program, which showed that the drug effectively reduced the hepatic fat content, improved liver histology (both MASH resolution and fibrosis improvement) and ameliorated biomarkers of liver damage [14,15].”
Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1
Aldroubi, B., Najjar, J. A., Youssef, T., Rizk, C., Abuamreh, B. A. M., Aramouni, K., Ghadieh, H. E., & Najjar, S. M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.48 · Cited by 8
Santol, J., Rajcic, D., Ortmayr, G., Hoebinger, C., Baranovskyi, T. P., Rumpf, B., Schuler, P., Probst, J., Aiad, M., Kern, A. E., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101226 · Cited by 9
GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action
Cansby, E., Caputo, M., Andersson, E., Saghaleyni, R., Henricsson, M., Xia, Y., Asiedu, B., Blüher, M., Svensson, L. T., Hoy, A. J., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100669 · Cited by 8
“Importantly, to date, only resmetirom, a liver-targeted thyroid hormone receptor (THR)-beta selective agonist, has been approved by the FDA for the treat-ment of MASH; however, it is effective only in 30% of patients at 1-year follow-up, and no long-term data are yet available (8).”
Folestad, E. B., & Falkevall, A. (2024) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2024.100559 · Cited by 9
Harvey, B. E. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01396-4 · Cited by 7
Woodard, J. S., Velji-Ibrahim, J., & Abrams, G. A. (2024) · Diseases · doi:10.3390/diseases12110288 · Cited by 8
“Resmetirom, a THR-beta agonist, has been FDA-approved as a liver-directed medication for subjects with MASLD and stages 2–3 fibrosis [16].”
Talha, M., Ali, M. H., Nadeem, Z. A., Akram, U., Saravanan, P. B., & Khalid, M. H. A. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002892 · Cited by 8
“Resmetirom, a THR agonist that targets fatty acid handling, is one of the promising drugs that ongoing trials are focused on [18].”
Zheng, Q., & Rui, L. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.75 · Cited by 7
Sun, Y., Yuan, X., Hu, Z., & Li, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116730 · Cited by 10
Ryu, G., Yoon, E. L., Kim, W., & Jun, D. W. (2025) · Diagnostics · doi:10.3390/diagnostics15030342 · Cited by 8
Thyroid dysfunction in MASLD: Results of a nationwide study
Yuan, S., Ebrahimi, F., Bergman, D., Vujković, M., Scorletti, E., Ruan, X., Chen, J., Hagström, H., & Ludvigsson, J. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101369 · Cited by 14
Schonfeld, E. A., Kierans, A. S., Fox, R. K., & Brandman, D. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2024.12.014 · Cited by 8
Merheb, C., Gerbal‐Chaloin, S., Casas, F., Diab‐Assaf, M., Daujat‐Chavanieu, M., & Feillet‐Coudray, C. (2025) · Nutrients · doi:10.3390/nu17061031 · Cited by 10
“Rezdiffra™ (resmetirom), a beta-selective agonist of the thyroid hormone receptor, was recently approved by the FDA for the treatment of MASH with moderate to advanced fibrosis without cirrhosis, in conjunction with a healthy diet and exercise [10,11].”
Fujiwara, N., Matsushita, Y., Tempaku, M., Tachi, Y., Kimura, G., Izuoka, K., Hayata, Y., Kawamura, S., Eguchi, A., Nakatsuka, T., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001360 · Cited by 14
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 8
MetALD: Genetic Factors and Clinical Outcomes
Israelsen, M. E., Trépo, E., Krag, A. A., & Stender, S. (2025) · Seminars in Liver Disease · doi:10.1055/a-2630-0952 · Cited by 9
Dijck, E. V., Laere, S. V., Logie, E., Timmermans, S., Fransén, E., Ibrahim, J., Kendall, T. J., Fallowfield, J. A., Mateiu, L. M., Libert, C., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01945-6 · Cited by 13
“Despite a breakthrough food and drug administration (FDA) approved therapy, resmetirom, a thyroid hormone receptor beta (THRB) agonist, many patients remain unresponsive to treatment [12, 13].”
Self-citationExploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives
Singh, A., Akhtar, A., & Shukla, P. (2025) · ADMET & DMPK · doi:10.5599/admet.2874 · Cited by 10
“Recently, the FDA approved resmetirom for non-cirrhotic MASH with moderate to advanced fibrosis, based on a Phase 3 clinical trial (NCT03900429), which demonstrated MASH resolution with at least one stage improvement in fibrosis [54].”
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 11
Abaalkhail, F. A., Sanai, F. M., Alswat, K., Alzanbagi, A., Al-Jedai, A. H., Alshehri, A., Alfadda, A. A., Alghamdi, H., Almadi, M. A., AlEissa, M., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_199_25 · Cited by 12
Ndaa, M., Pandya, P., Swensson, J., Samala, N. R., Ajaz, S., Joshi, D., Ayoub, W. S., & Akisik, F. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.205 · Cited by 12
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 8
Rozani, S., Dalamaga, Μ., Weber, G., & Grützmann, R. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100410 · Cited by 7
Windell, D., Magness, A. J., Beyer, C., Thomaides-Brears, H. B., Larkin, S. J., Hobson, K., Aljabar, P., Fleming, K., Fryer, E., Kendall, T. J., et al. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2025-210311 · Cited by 9
Li, L., Mao, X., Lee, C., Lui, D. T. W., Hui, R. W., Mak, L., Yuen, M., Cheung, K. S., & Seto, W. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101661 · Cited by 11
Huybrechts, T., Franck, K., Steenackers, E., & Hul, W. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211054 · Cited by 8
“It is approved for adult patients with noncirrhotic MASH, where clinical trials revealed improvements in hepatic fat, liver fibrosis and positive effects on metabolic health and quality of life [10].”
Peng, Q., Hao, L., Li, S., Yu, F., Li, N., & Hu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640873 · Cited by 9
Nutrition in MASLD: a patient focused, evidence-based clinician’s guide
Pekarska, K., Brennan, P. N., Wajcman, D. I., Towey, J., Cox, L., Weatherby, K., McPherson, S., Stine, J., Willemse, J., Li, W., et al. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103183 · Cited by 8
Hepatic Fibrosis and Liver Cancer
Anton, A., Friedman, S. L., & Cogliati, B. (2025) · Seminars in Liver Disease · doi:10.1055/a-2779-4937 · Cited by 11
Tincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 8
Self-citationTamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
“Japanese cohorts suggest no difference between lean and non-lean MASLD, while a French cohort reported significantly higher mortality in lean has been approved in Western countries [84, 85].”
Tevonian, E. N., Kan, E. L., Maniar, K. K., Wang, A. J., Datta, A., Kamm, R. D., Lauffenburger, D. A., & Griffith, L. G. (2026) · Nature Communications · doi:10.1038/s41467-025-68031-6 · Cited by 14
Stern, U. M., Wagenpfeil, G., Weber, S. N., Alqahtani, S. A., Michel, M. S., & Schattenberg, J. M. (2026) · European Journal of Nutrition · doi:10.1007/s00394-025-03870-z · Cited by 13
“Dietary interventions remain the cornerstone of treatment for MASLD by itself or in combination with recently approved therapies [83].”
Self-citationRYK is a GPNMB receptor that drives MASH
Xi, Y., Zeng, W., Luo, J., Zhou, J., Wang, L., Sun, J., He, Z., Li, W., Zhu, S., Qi, W., et al. (2026) · Nature · doi:10.1038/s41586-026-10160-z · Cited by 10
Nóvoa, E., Parracho, T., Inderhees, J., Rodriguez, A., Riobello, C., Iglesias-Moure, J., Fernández‐Iglesias, A., Martínez-Martínez, S., Senra, A., Seoane, S., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.01.016 · Cited by 10
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
Mann, J. P., Lefere, S., Buytaert, M., Alisi, A., Arikan, C., Brecelj, J., Brown, R. M., Degrassi, I., Fiore, G., Fitzpatrick, E., et al. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70490 · Cited by 10
Self-citationLi, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 11
“62 Targeting bile acid metabolism Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily expressed primarily in the liver and intestine, is activated by bile acids (BAs), influencing glucose and lipid metabolism.”
Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Nendouvhada, L. P., Sibuyi, N. R. S., Fadaka, A. O., Meyer, S., Madiehe, A. M., Meyer, M., & Gabuza, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115571 · Cited by 8
“The two doses showed adverse effects in 90% of the patients; nausea and diarrhea were more common in treated patients compared to those receiving the placebo [54].”
ResultA Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Hong, H., & Choi, J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.048 · Cited by 7
Letter: Drug interaction in resmetirom times
Zhou, X., Liu, W., Targher, G., Byrne, C. D., & Zheng, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18062 · Cited by 8
“4 Thus, when designing clinical trials for MASH in the future, the focus should at least be on both liver-related and cardiovascular events.”
Naujack, A.-M., Krause, C., Britsemmer, J. H., Taege, N., Mittag, J., & Kirchner, H. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0080 · Cited by 9
“A reduced availability of T3 can be rescued by levothyroxine, as shown in previous studies (32) or by the use of resmetirom, a phase 3 clinical trial liver-specific THRB agonist (33).”
Liver-specific thyroid hormone receptor-β agonism alleviates alcoholic steatohepatitis (ASH) in mice
Shahi, A., Yadav, A., Rajak, S., Raza, S., Tewari, A., Gupta, P., & Sinha, R. A. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150742 · Cited by 7
Yan, R., Liu, L., Tzoulaki, I., Fan, J.-G., Targher, G., Yuan, Z., & Zhao, J. (2024) · Liver International · doi:10.1111/liv.16150 · Cited by 11
Kaya, E., Syn, W., & Manka, P. P. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001083 · Cited by 7
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002150 · Cited by 10
“11 In addition to these effects, signi fi cant reductions in plasma LDL levels have been consistently observed with resmetirom treatment, which might be associated with a decrease in cardiovascular mortality risk.”
InfluentialSelf-citationPettinato, M., Furiosi, V., Carleo, R., Volpe, L. B., Guo, S., Mannella, V., Musco, G., Gilberti, E., Palma, G. D., Federico, G., et al. (2025) · Liver International · doi:10.1111/liv.70163 · Cited by 9
“However, this approach reverses MASH and fibrosis in only about one-third of patients [4].”
Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update
Fallowfield, J. A., & Ramos, M. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2341878 · Cited by 8
“In the pivotal phase 3 randomized placebo-controlled serial biopsy trial in patients with NASH and liver fibrosis (MAESTRO-NASH; NCT03900429), both doses of resmetirom (80 mg and 100 mg) met the primary endpoints of steatohe-patitis resolution and no worsening of fibrosis on liver biopsy [10].”
Combination Treatment in MASLD: The Next Frontier
Tsochatzis, E. A., & Noureddin, M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.021 · Cited by 7
Self-citationWe Need Simpler and More Integrated Guidelines in Cardio-Kidney-Metabolic Diseases
Ferreira, J. P., & Zannad, F. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.025 · Cited by 7
Papachristoforou, E., Kong, K., Colella, F., Tam, J., Luft, J., Sutherland, E. F., Veizades, S. A., Grzelka, M., Qui, P. K., Asif, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.27.671899 · Cited by 7
Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis
Shi, Z., Liu, X., Wu, S., Song, N., Tang, Q., Li, H., Luo, S., Chan, A. S. C., Cai, X., Liu, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00834 · Cited by 7
Helal, E., Elgebaly, F., Mousa, N., Elbaz, S., Abdelsalam, M., Abdelkader, E., El‐Sehrawy, A. A. M. A., El‐Wakeel, N., El-Emam, O., Hashem, M., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-02032-x · Cited by 9
“Resmetirom targets the liver and has shown effectiveness in reducing hepatic fat, improving liver health, and reducing biomarkers of liver damage without affecting weight or glucose metabolism [38].”
BackgroundXia, T., Ni, J., Ni, Y., Wu, X., Du, K., Wan, X., & You, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1454193 · Cited by 8
Dawn of an era of effective treatments for MAFLD
Gofton, C., & George, J. (2024) · Portal hypertension & cirrhosis · doi:10.1002/poh2.96 · Cited by 7
Li, Y., Jiao, T., Cheng, X., Liu, L., Zhang, M., Li, J., Wang, J., Hu, S., Li, C., Yu, T., et al. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf004 · Cited by 6
“…metabolic function, while antagonism can inhibit steatosis and reactivate hepatic FXR. Resmetirom, a thyroid hormone receptor beta (THR-β ) agonist, was recently approved by the United States Food and Drug Administration (FDA) for MASH treatment, but only for patients with F2/F3 fibrosis [35].”
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Capinha, F., Carvalhana, S. C., & Cortez‐Pinto, H. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08912-4 · Cited by 7
“[92] There are medications that although approved for other indications demonstrated benefits for MASH in clinical trials and should be considered when other indications are present.”
Sun, X., Yang, Z., Li, M., Gong, S., Miao, X., Wang, B., Kong, X., & Zhu, Q. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123575 · Cited by 8
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6
“43 reported that MASH resolved without worsening of hepatic fibrosis in 25.9% of patients in the 80 mg resmetirom group and 29.9% in the 100 mg group.”
InfluentialPebriana, R. B., Chen, T., Derks, R. J. E., Blomberg, N., Grefhorst, A., Mohammed, Y., Nieuwdorp, M., Verheij, J., Doukas, M., Rensen, P. C. N., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100845 · Cited by 7
“Only last year, the selective thyroid hormone receptor beta (THR β )-selective agonist resmetirom was conditionally approved by the FDA as the first drug for the treatment of fibrotic MASH (15, 16).”
Thyroid Hormone Analogs: Recent Developments
Freund, M., van Geest, F. S., Groeneweg, S., van Geest, F. S., & Visser, W. E. (2025) · Thyroid · doi:10.1089/thy.2025.0245 · Cited by 8
Ashi, S. I. A., Shah, R., Iftikhar, N., Lingvay, I., Kinaan, M., & Mansi, I. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16657 · Cited by 6
“48 Resmetriom resulted in resolution of hepatic steatosis with no worsening in fibrosis but has not been shown to decrease the risk of cardiovascular disease.”
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
“…proliferator-activated receptor (PPAR) agonist, semaglutide, a glucagon-like peptide 1 (GLP-1) receptor (GLP-1 R) agonist, efruxifermin and pegozafer-min, two injectable fibroblast growth factor (FGF) 21 agonists, and survodutide, a dual GLP1R/glucagon receptor (GCGR) agonist (Table 1) [14].”
Future potential therapeutics to treat MASH
Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 10
Pi, S., Zhang, S., Zhang, J., Guo, Y., Li, Y., Deng, J., & Du, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1626352 · Cited by 190
“…(a thyroid hormone receptor β agonist) is the only MASH-targeting drug with positive results from a registrational phase III clinical trial (18), though long-term safety (e.g., thyroid/gonadal effects) and hard endpoint benefits require further validation; farnesoid X receptor (FXR)…”
Olveira, A., Crespo, J., Ibáñez, L., Gallego‐Durán, R., Calleja, J. L., Aller, R., Sòria, A., Gómez‐Camarero, J., Martín‐Mateos, R., Benlloch, S., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.023 · Cited by 10
Self-citationLambooij, J. M., Chavanelle, V., Vallier, M., van der Zande, H. J. P., Otero, Y. F., Otto, F., Schuurman, R., Joubioux, F. L., Maugard, T., Giera, M. A., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00033-z · Cited by 7
Maior, M. D. R. M. S., Ribeiro, N. D. L. I., Silva, H. V. V., Lopes, E. P., & Costa, E. C. (2025) · Biomedicines · doi:10.3390/biomedicines13092162 · Cited by 10
“In a phase 3 randomized controlled trial, resmetirom showed greater efficacy compared to placebo in terms of resolution of NASH and improvement in liver fibrosis [130].”
Zhang, F., Meng, Y., Zhao, B., Li, Z., Han, M., Li, M., & Zhou, Y. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01484-1 · Cited by 8
“The two primary endpoints were MASH remission (defined as a ≥ 2-point reduction in NAFLD activity score), no worsening of fibrosis, at least one stage of fibrosis improvement, and no worsening of NAFLD activity score after 52 weeks of treatment [32].”
Qiao, Y., Zhang, Y., Sun, C., Jin, Q., Qu, P., Li, Z., Qiu, Y., Meng, H., Peng, D., & Peng, L. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156416 · Cited by 7
Resmetirom and beyond: A new era in MASLD therapeutics
Johnson-Moore, T., Simmons, D., Okafor, A. C., Washington, D., & Baskaran, P. (2025) · Liver Research · doi:10.1016/j.livres.2025.10.004 · Cited by 6
Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease
De, A., Chalasani, N., & Duseja, A. K. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.09.003 · Cited by 7
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
“…with MASH, as patients treated with resmetirom exhibited a significantly higher rate of both MASH resolution (up to 20.2 %, placebo-subtracted) and fibrosis improvement of at least one stage of fibrosis (up to 11.7 % placebo-subtracted) in the interim analysis of a large ongoing phase 3 RCT [57].”
InfluentialSelf-citationCurrent treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
“A few weeks later, in March 2024, the U.S. FDA approved resme-tirom for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2-F3) in the U.S. [147 ].”
Abdeljawad, M. M., Hasan, M. T., Fareed, A., Abouelmagd, K., Saed, S. A. A., Ali, S., Keshk, M., Khan, M., Taha, N. A., & Taha, A. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103786 · Cited by 6
FAM134B controls collagen I dynamics in hepatic stellate cell-driven fibrosis
Misra, J., Hanquier, Z., Baxter, R., Barupala, N. P., Jackson, A. R., & Maiers, J. L. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00170.2025 · Cited by 7
Simonetto, D. A., Rushlow, D. R., Liu, K., Calleri, A., Kassmeyer, B. A., Lennon, R. J., Rattan, P., Bernard, M., Singh, G., Deyo-Svendsen, M. E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04058-y · Cited by 10
Panuganti, V. K., Alluri, C. V., Mohammad, J., Dundigalla, M. R., Madala, P. K., KSSVV, S., & shaik, A. H. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113658 · Cited by 6
Sriperumbuduri, S., Saravanan, P. B., Gupta, G., & Sanyal, A. J. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103757 · Cited by 12
“86,87 Another class under investigation is farnesoid X receptor agonists, including obeticholic acid, which modulate bile acid signaling, regulate lipid metabolism, and exert anti-inflammatory effects.”
Self-citationNew Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
Jirapinyo, P., Papke, D. J., García–Tsao, G., Ryou, M. K., Zhao, L., Zucker, S. D., & Thompson, C. C. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2026.02.042 · Cited by 6
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
“However, given that both FDA-approved medications to treat MASH have been approved for individuals with MASH and F2 or F3, 7,8 it makes sense to focus recommendations to identify those patients that would benefit from specific pharmacological treatment.”
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.